Werth V, Pike M, Merrill J, Morand E, van Vollenhoven R, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. J of Skin [Internet]. 2023 Mar. 13 [cited 2024 Jul. 4];7(2):s114. Available from: https://jofskin.org/33014/index.php/skin/article/view/1964